DK2116241T3 - Farmaceutisk sammensætning - Google Patents
Farmaceutisk sammensætning Download PDFInfo
- Publication number
- DK2116241T3 DK2116241T3 DK08702781.9T DK08702781T DK2116241T3 DK 2116241 T3 DK2116241 T3 DK 2116241T3 DK 08702781 T DK08702781 T DK 08702781T DK 2116241 T3 DK2116241 T3 DK 2116241T3
- Authority
- DK
- Denmark
- Prior art keywords
- acid
- salt
- pharmaceutical composition
- compound
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (9)
1. Farmaceutisk sammensætning omfattende 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazol, som er repræsenteret ved formel (1):
og en forbindelse med en chelaterende evne, hvor forbindelsen med en chelaterende evne er en eller flere arter udvalgt fra gluconsyre eller et salt deraf, gluceptinsyre eller et salt deraf, vinsyre eller et salt deraf, glucuronsyre eller et salt deraf, glucarsyre eller et salt deraf, ascorbinsyre eller et salt deraf, ethylendiamintetraeddikesyre eller et salt deraf, citronsyre eller et salt deraf og diethylamin; hvor indholdet af forbindelsen repræsenteret ved formel (1) i den farmaceutiske sammensætning er 1 til 10 masseprocent, og mængden af forbindelsen med en chelaterende evne i den farmaceutiske sammensætning er 0,01 til 2 masseprocent.
2. Farmaceutisk sammensætning ifølge krav 1, hvor saltet af gluconsyre, gluceptinsyre, vinsyre, glucuronsyre, glucarsyre eller ascorbinsyre er et jord-alkalimetalsalt.
3. Farmaceutisk sammensætning ifølge krav 1 eller 2, hvor forbindelsen, som er repræsenteret ved formel (1), er en RS-SR racemisk blanding af en isomer med en stereo-struktur, der er repræsenteret ved formel (2):
og en isomer, som har en stereo-struktur, der er repræsenteret ved formel (3)
4. Farmaceutisk sammensætning ifølge et af kravene 1 til 3, som er en injektion.
5. Farmaceutisk sammensætning omfattende 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazol, som er repræsenteret ved formel
og en forbindelse med en chelaterende evne til anvendelse ved forøgelse af strålingsfølsomhed af hypoxiske kræftceller inden for strålebehandling af kræft, hvor forbindelsen med en chelaterende evne er en eller flere arter udvalgt fra en gluconsyre eller et salt deraf, gluceptinsyre eller et salt deraf, vinsyre eller et salt deraf, glucuronsyre eller et salt deraf, glucarsyre eller et salt deraf, ascorbinsyre eller et salt deraf, ethylendiamintetraeddikesyre eller et salt deraf, citronsyre eller et salt deraf og diethylamin, hvor indholdet af forbindelsen repræsenteret ved formel (1) i den farmaceutiske sammensætning er 1 til 10 masseprocent, og mængden af forbindelsen med en chelaterende evne i den farmaceutiske sammensætning er 0,01 til 2 masseprocent.
6. Farmaceutisk sammensætning til anvendelse ifølge krav 5, hvor saltet af gluconsyre, gluceptinsyre, vinsyre, glucuronsyre, glucarsyre eller ascorbinsy- re er et jordalkalimetalsalt.
7. Farmaceutisk sammensætning til anvendelse ifølge krav 5 eller 6, hvor forbindelsen, der er repræsenteret ved formel (1), er en RS-SR racemisk blanding af en isomer med en stereo-struktur, der er repræsenteret ved formel (2), og en isomer med en stereo-struktur, der er repræsenteret ved formel (3).
8. Farmaceutisk sammensætning til anvendelse ifølge et af kravene 5 til 7, hvor sammensætningen er en injektion.
9. Farmaceutisk sammensætning ifølge krav 1 til anvendelse som en strå-lingssensibilisator inden for strålebehandling af kræft.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007016789 | 2007-01-26 | ||
| PCT/JP2008/000040 WO2008090732A1 (ja) | 2007-01-26 | 2008-01-17 | 医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2116241T3 true DK2116241T3 (da) | 2016-06-06 |
Family
ID=39644307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08702781.9T DK2116241T3 (da) | 2007-01-26 | 2008-01-17 | Farmaceutisk sammensætning |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8541459B2 (da) |
| EP (1) | EP2116241B1 (da) |
| JP (1) | JP5297815B2 (da) |
| KR (1) | KR101408680B1 (da) |
| CN (1) | CN101621997B (da) |
| DK (1) | DK2116241T3 (da) |
| HK (1) | HK1138774A1 (da) |
| TW (1) | TWI500421B (da) |
| WO (1) | WO2008090732A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5297815B2 (ja) | 2007-01-26 | 2013-09-25 | 株式会社ポーラファルマ | 医薬組成物 |
| CN101541324B (zh) | 2007-06-14 | 2011-06-15 | 株式会社宝丽制药 | 医药组合物 |
| CN101642452B (zh) * | 2008-08-06 | 2014-05-28 | 株式会社宝丽制药 | 脑肿瘤用放射线敏化剂 |
| JP2015091766A (ja) * | 2013-09-30 | 2015-05-14 | 株式会社ポーラファルマ | 癌治療支援システム |
| US20190298835A1 (en) * | 2018-03-29 | 2019-10-03 | U.S. Army Research Laboratory | Administration of tailored feedstock to increase antibiotic susceptibility |
| US11684597B2 (en) | 2019-01-28 | 2023-06-27 | The United States Of America As Represented By The Secretary Of The Army | Administration of tailored feedstock to increase nitro-containing amphenicol antibiotic susceptibility |
| CN110105371B (zh) * | 2019-05-06 | 2020-10-27 | 深圳万乐药业有限公司 | 一种多拉达唑原料药中的杂质及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4462992A (en) * | 1982-02-08 | 1984-07-31 | Research Corporation | Nitroimidazole radiosensitizers for hypoxic tumor cells and compositions thereof |
| US4797397A (en) * | 1987-07-31 | 1989-01-10 | Warner-Lambert Company | 2-nitroimidazole derivatives useful as radiosensitizers for hypoxic tumor cells |
| US5036060A (en) | 1988-07-25 | 1991-07-30 | Fujisawa Usa, Inc. | Cyclophosphamide |
| JP2701482B2 (ja) * | 1989-10-23 | 1998-01-21 | オムロン株式会社 | ソレノイド装置 |
| JP2626727B2 (ja) | 1990-01-26 | 1997-07-02 | ポーラ化成工業株式会社 | ２―ニトロイミダゾール誘導体、その製造法及びこれを有効成分とする放射線増感剤 |
| JP3223258B2 (ja) | 1992-06-24 | 2001-10-29 | 株式会社キーエンス | 稼働状態監視装置 |
| ATE236131T1 (de) | 1992-12-18 | 2003-04-15 | Pola Chem Ind Inc | Optisch aktives 2-nitroimidazolderivat, verfahren zu seiner herstellung und ein intermediat zu seiner herstellung |
| JP3136306B2 (ja) | 1993-10-26 | 2001-02-19 | 丸石製薬株式会社 | 静脈注射用ニトロプルシドナトリウム注射剤 |
| ES2184812T3 (es) | 1994-11-28 | 2003-04-16 | Abbott Lab | Patrones para el dosificado inmunologico de esteroides estabilizados en solucion acuosa. |
| US5834315A (en) * | 1994-12-23 | 1998-11-10 | Coulter Corporation | Cyanide-free reagent and method for hemoglobin determination and leukocyte differentitation |
| US5700825A (en) * | 1995-03-31 | 1997-12-23 | Florida State University | Radiosensitizing diamines and their pharmaceutical preparations |
| JPH0977667A (ja) | 1995-09-12 | 1997-03-25 | Pola Chem Ind Inc | 核酸塩基水酸化物消去促進剤 |
| DE69600289T2 (de) * | 1995-09-19 | 1998-09-03 | Mitsubishi Gas Chemical Co | Biologisch abbaubares wasserlösliches Polymer |
| US5961955A (en) * | 1997-06-03 | 1999-10-05 | Coulter Pharmaceutical, Inc. | Radioprotectant for peptides labeled with radioisotope |
| WO1999009997A1 (en) * | 1997-08-26 | 1999-03-04 | Board Of Regents, The University Of Texas System | Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections |
| GB9925127D0 (en) | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
| EP1311301A2 (en) * | 2000-07-06 | 2003-05-21 | Bristol-Myers Squibb Pharma Company | Stable radiopharmaceutical compositions and methods for preparation thereof |
| EP1476428B1 (en) * | 2002-02-22 | 2010-11-17 | Pharmacia & Upjohn Company LLC | Pyridyl sulfone derivatives as 5-ht6 receptor ligands |
| US20040214215A1 (en) * | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| BRPI0409133B8 (pt) | 2003-04-08 | 2021-05-25 | Progenics Pharm Inc | preparações farmacêuticas estavéis compreendendo metilnaltrexona |
| JP4288337B2 (ja) | 2003-07-08 | 2009-07-01 | 株式会社ポーラファルマ | 低酸素性細胞増感剤の増感効果の鑑別法及び低酸素条件下アポトーシス・シグナル保持剤 |
| GB0501192D0 (en) | 2005-01-20 | 2005-03-02 | Resolution Chemicals Ltd | Stable prostaglandin-containing compositions |
| JP2007106736A (ja) * | 2005-09-14 | 2007-04-26 | Pola Chem Ind Inc | 注射用の医薬組成物 |
| JP2007191417A (ja) * | 2006-01-19 | 2007-08-02 | Pola Chem Ind Inc | 医薬用の組成物 |
| JP5297815B2 (ja) | 2007-01-26 | 2013-09-25 | 株式会社ポーラファルマ | 医薬組成物 |
| CN101541324B (zh) | 2007-06-14 | 2011-06-15 | 株式会社宝丽制药 | 医药组合物 |
-
2008
- 2008-01-17 JP JP2008554998A patent/JP5297815B2/ja not_active Expired - Fee Related
- 2008-01-17 CN CN2008800029708A patent/CN101621997B/zh not_active Expired - Fee Related
- 2008-01-17 KR KR1020097013776A patent/KR101408680B1/ko not_active Expired - Fee Related
- 2008-01-17 EP EP08702781.9A patent/EP2116241B1/en active Active
- 2008-01-17 US US12/523,067 patent/US8541459B2/en active Active
- 2008-01-17 WO PCT/JP2008/000040 patent/WO2008090732A1/ja active Application Filing
- 2008-01-17 DK DK08702781.9T patent/DK2116241T3/da active
- 2008-03-07 TW TW097108192A patent/TWI500421B/zh active
-
2010
- 2010-06-03 HK HK10105492.0A patent/HK1138774A1/xx not_active IP Right Cessation
-
2012
- 2012-01-31 US US13/362,545 patent/US8420687B2/en active Active
- 2012-01-31 US US13/362,527 patent/US8450356B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101621997A (zh) | 2010-01-06 |
| JP5297815B2 (ja) | 2013-09-25 |
| EP2116241A4 (en) | 2010-07-21 |
| EP2116241A1 (en) | 2009-11-11 |
| HK1138774A1 (en) | 2010-09-03 |
| US20100076042A1 (en) | 2010-03-25 |
| WO2008090732A1 (ja) | 2008-07-31 |
| JPWO2008090732A1 (ja) | 2010-05-20 |
| US20120129905A1 (en) | 2012-05-24 |
| US8450356B2 (en) | 2013-05-28 |
| US8420687B2 (en) | 2013-04-16 |
| EP2116241B1 (en) | 2016-04-27 |
| US8541459B2 (en) | 2013-09-24 |
| TW200938190A (en) | 2009-09-16 |
| US20120130148A1 (en) | 2012-05-24 |
| KR101408680B1 (ko) | 2014-06-17 |
| CN101621997B (zh) | 2013-05-08 |
| TWI500421B (zh) | 2015-09-21 |
| KR20090102782A (ko) | 2009-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2116241T3 (da) | Farmaceutisk sammensætning | |
| EP0858329B1 (fr) | Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation | |
| EP2307056B1 (en) | Stabilized aqueous formulation containing paracetamol | |
| US8258166B2 (en) | Pharmaceutical composition | |
| US5164405A (en) | Nicardipine pharmaceutical composition for parenteral administration | |
| KR101838764B1 (ko) | (ｅ)-4-카복시스티릴-4-클로로벤질설폰의 개선된 안정한 수성 제형 | |
| RU2414230C1 (ru) | Средство, обладающее капилляропротекторной активностью | |
| EP3593819A1 (en) | Compositions for therapeutic uses containing 5-htp and carbidopa | |
| JP2007106736A (ja) | 注射用の医薬組成物 | |
| RU2538803C1 (ru) | Мембранопротекторное средство | |
| JP2007191418A (ja) | 医薬用の組成物 | |
| JP2007191417A (ja) | 医薬用の組成物 | |
| JP2007091674A (ja) | 注射用の医薬組成物 | |
| JP2010184936A (ja) | 放射線被爆患者の処置方法 |